TGF-beta 2

TGF-beta 2 Informations sur la molécule

Nom anglais	Transforming growth factor beta 2	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	6	Alias de la cible	TGF-beta-2，BSC-1 Cell Growth Inhibitor，Polyergin，Glioblastoma-Derived T-Cell Suppressor Factor，Cetermin，LDS4，TGFB2，Transforming Growth Factor， Beta 2，Transforming Growth Factor Beta-2 Proprotein，TGF-Beta2，Transforming Growth Factor Beta 2，G-TSF，Transforming Growth Factor beta2，LAP，Prepro-Transforming Growth Factor Beta-2
Phase de R&D la plus avancée	Phase 3 Clinical

Nom anglais	Transforming growth factor beta 2
Alias de la cible	TGF-beta-2，BSC-1 Cell Growth Inhibitor，Polyergin，Glioblastoma-Derived T-Cell Suppressor Factor，Cetermin，LDS4，TGFB2，Transforming Growth Factor， Beta 2，Transforming Growth Factor Beta-2 Proprotein，TGF-Beta2，Transforming Growth Factor Beta 2，G-TSF，Transforming Growth Factor beta2，LAP，Prepro-Transforming Growth Factor Beta-2
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	6
Phase de R&D la plus avancée	Phase 3 Clinical

TGF-beta 2 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
Tag Free (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
TG2-H4215	Human	HEK293	Human TGF-Beta 2 / TGFB2 Protein, Tag Free				Ajouter au panier

Quantité totale1

TGF-beta 2Contexte de la molécule

Transforming growth factor beta 2 ( TGFB2) is also known as TGF-β2, G-TSF, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The TGFB2 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB2 protein can inhibit the T cell growth by IL-2-dependent. and can inhibit immune surveillance during tumor development, the protein promoting tumor growth with an autocrine manner. TGF-β2 can affect the viability of killer cells and reduce the expression of IL-2, IL-6, IL-10, IFN-γ and other cytokines.TGFB2 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages.

TGF-beta 2Alias de la molécule

TGFB2,MGC116892,TGFβ2,TGF-beta2

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Trabedersen	AP 2/09-DS; AP-12009; OT-201; AP-2/09; AP-2/09-DS; OT-101	Phase 3 Clinical	Isarna Therapeutics Gmbh	Astrocytoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Diffuse Intrinsic Pontine Glioma; Glioblastoma; Lung Neoplasms; Melanoma; Mesothelioma; Pancreatic Neoplasms; Solid tumours	Details
Bintrafusp alfa	M-7824; GSK-4045154; MSB-0011359C	Phase 3 Clinical	Merck Serono	Anus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop	Details
Nisevokitug	NIS-793	Phase 3 Clinical	Xoma Corp	Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential	Details
ISTH-0036	ISTH-0036	Phase 2 Clinical	Isarna Therapeutics Gmbh	Diabetic macular oedema; Glaucoma, Open-Angle; Wet Macular Degeneration	Details
Tosposertib phosphate	TU-2218; NCE401; NCE-401	Phase 2 Clinical	TiumBio Co Ltd	Idiopathic Pulmonary Fibrosis; Solid tumours	Details
LP-008	LP-008	Phase 1 Clinical	Lepu Biopharma Co Ltd	Solid tumours	Details